Genetic Alterations of SMYD4 in Solid Tumors Using Integrative Multi-Platform Analysis

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genomics

Background:

• SMYD4, a member of the SMYD family, possesses lysine methyltransferase activity.
• The specific roles of SMYD4 in cancer development and progression remain largely uncharacterized.

Purpose of the Study:

• To investigate genetic alterations in the SMYD4 gene across prevalent solid tumors.
• To evaluate the potential of SMYD4 as a diagnostic or prognostic biomarker in cancer.

Main Methods:

• Integrative analysis of mutations, copy number alterations (CNAs), and mRNA expression of SMYD family genes.
• Utilized data from The Cancer Genome Atlas (TCGA), cBioPortal, and the Catalogue of Somatic Mutations in Cancer (COSMIC).

Main Results:

• SMYD4 mutations were infrequent and lacked biomarker potential.
• Consistent heterozygous loss and downregulation of SMYD4 were observed across most evaluated tumors.
• Low SMYD4 expression correlated with significantly poorer overall survival in stomach (STAD) and lung adenocarcinoma (LUAD).

Conclusions:

• SMYD4 functions as a tumor suppressor in the majority of analyzed cancers.
• The consistent downregulation and association with poorer survival highlight SMYD4's potential as a valuable cancer biomarker.